| European Case Law Identifier: | ECLI:EP:BA:1993:T034991.19930310 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 10 March 1993 | ||||||||
| Case number: | T 0349/91 | ||||||||
| Application number: | 81900044.9 | ||||||||
| IPC class: | G01N 33/574 G01N 33/577 A61K 39/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Monoclonalhybridoma antibody specific for high molecular weight carcinoembryonic antigen | ||||||||
| Applicant name: | The Wistar Institute | ||||||||
| Opponent name: | F. Hoffmann-La Roche & Co. Aktiengesellschaft | ||||||||
| Board: | 3.4.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Sufficient disclosure - no; rectified by amendment of claims Novelty (yes) Inventive step (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t910349eu1.html
Date retrieved: 17 May 2021